Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation
about
Optimizing Treatment of Familial Hypercholesterolemia in Children and AdolescentsStructural and functional analysis of the CspB protease required for Clostridium spore germinationThe multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functionsPhysiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol.Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.Identification of genomic features in the classification of loss- and gain-of-function mutation.Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.PCSK9 Inhibitors: potential in cardiovascular therapeutics.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor.An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.In Vitro Assays for the Discovery of PCSK9 Autoprocessing Inhibitors.
P2860
Q26798119-C4E0357D-E9CF-4AD8-A8E9-D7F08B425DF6Q27676376-7FDAE01E-B04C-4DB3-A022-34B35AC23D02Q30541820-ABB2A78D-2093-40FA-840D-1A20CF8623F8Q33599961-86DC10C3-BAD4-49BE-9651-C92BEE59A6D3Q34355679-4EBBC60B-0312-4855-B2F3-929F4074F26DQ34458693-F6FD8DF6-6949-422F-A953-37DB088FF89AQ34723257-538A485D-1333-4944-84F5-4CD2B7BB085DQ34951227-5567B8E2-6993-4D8E-898E-14FC8DA89182Q35014317-EE4BA593-ACCA-463B-AA1D-AEB7B823EE26Q35217031-B802E595-2BC4-4124-BCBF-EE48EC02B09AQ35653073-9E0FA804-2CE6-49D3-B929-7D25D36E3291Q35883857-BF33863C-5A57-4FEB-A68B-76B83033055CQ38075818-10867F97-3691-4270-92D0-C69678370F12Q38109960-B9EA5A9F-DB10-4598-93DB-0EE150682A8AQ38381808-D077B57A-8D35-4D9D-91A4-B36171F9A408Q38855416-1093BE15-3BA6-4C5D-98C8-C848CC726B53Q39030028-0C0AAC3B-B49E-408E-8666-63C4A7C76DEEQ39175455-F07D343E-B04A-4866-BDB5-332FE93EAE69Q39237132-40E353DE-B0E8-40EE-BF38-5183902C2270Q40445739-BB30FCB2-C510-4014-8B20-A689AC9328CBQ42367561-A9B1A86A-6FDC-4EFD-99AB-C18977DEB356Q42717872-7563A1DD-EF6F-4B27-AD00-7465380B3104Q45401315-BBEB349B-8F9E-4176-8DA4-E9395147EC6CQ47273218-D3038B94-01F5-4D2E-850F-1AECBE939F7DQ47909228-3999E081-141A-4AC9-8F58-F3F6E45552CFQ53061949-5D02AF2B-EC81-47CC-AAA9-AC1CE233D94F
P2860
Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Loss- and gain-of-function PCS ...... in receptor (LDLR) degradation
@en
Loss- and gain-of-function PCS ...... in receptor (LDLR) degradation
@nl
type
label
Loss- and gain-of-function PCS ...... in receptor (LDLR) degradation
@en
Loss- and gain-of-function PCS ...... in receptor (LDLR) degradation
@nl
prefLabel
Loss- and gain-of-function PCS ...... in receptor (LDLR) degradation
@en
Loss- and gain-of-function PCS ...... in receptor (LDLR) degradation
@nl
P2860
P356
P1476
Loss- and gain-of-function PCS ...... in receptor (LDLR) degradation
@en
P2093
Josée Hamelin
Suzanne Benjannet
P2860
P304
33745-33755
P356
10.1074/JBC.M112.399725
P407
P577
2012-08-08T00:00:00Z